Bobak Azamian is President, Chief Executive Officer and Board Chairman of Tarsus Pharmaceuticals, Inc. (TARS). The company reported total compensation of $6,617,979 for fiscal year 2025.
| Salary | $726,333 |
|---|---|
| Bonus | $0 |
| Stock awards | $2,648,284 |
| Option awards | $2,651,487 |
| Non-equity incentive plan | $555,700 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $36,175 |
| Total | $6,617,979 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Tarsus Pharmaceuticals, Inc. filed April 28, 2026, accession 0001819790-26-000028.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bobak Azamian this page | President, Chief Executive Officer and Board Chairman | $6,617,979 |
| Aziz Mottiwala | Chief Commercial Officer | $2,789,529 |
| Jeffrey Farrow | Chief Financial Officer and Chief Strategy Officer | $2,677,617 |
| Seshadri Neervannan | Chief Operating Officer | $2,628,172 |
| Bryan Wahl | General Counsel and Corporate Secretary | $2,560,205 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Tarsus Pharmaceuticals, Inc. compensation brief.
Bobak Azamian's compensation sits inside Tarsus Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.